Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating activities
Net loss	$ (207,298)	$ (146,227)	$ (68,606)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation expense	12,254	6,769	6,093
Noncash lease expense	7,028	3,266
Share-based compensation expense	43,251	24,761	13,124
Intangible assets amortization	1,699	1,703	1,698
Investment amortization	7,233	773	(4,463)
Fair value adjustment of convertible preferred stock warrant			2,266
Other	(78)	71	359
Changes in operating assets and liabilities:
Accounts receivable, net	(7,362)	2,613	(7,817)
Inventory	(5,200)	(4,994)	(1,231)
Prepaid expenses and other current assets	1,286	(1,362)	(8,576)
Accounts payable and accrued liabilities	3,940	7,495	6,149
Deferred rent			78
Operating lease right-of-use assets and liabilities	8,522	(886)
Deferred revenue	(57,727)	(43,389)	266,927
Other	(275)	(276)	(597)
Net cash (used in) provided by operating activities	(192,727)	(149,683)	205,404
Investing activities
Purchases of property and equipment	(61,746)	(18,803)	(11,200)
Purchases of marketable securities	(316,544)	(694,965)	(884,217)
Proceeds from sales and maturities of marketable securities	559,500	596,724	413,720
Net cash provided by (used in) investing activities	181,210	(117,044)	(481,697)
Financing activities
Proceeds from exercise of stock options	26,717	21,748	4,055
Proceeds from public offering of common stock, net of underwriting discounts and commissions		272,160	320,850
Payment of public offering costs, net		(321)	(4,986)
Proceeds from issuance of common stock upon the exercise of a common stock warrant			9
Proceeds from initial capital contributions for Digital Biotechnologies, Inc.	429
Other			(12)
Net cash provided by financing activities	27,146	293,587	319,916
Net increase in cash, cash equivalents and restricted cash	15,629	26,860	43,623
Cash, cash equivalents and restricted cash at beginning of year	125,574	98,714	55,091
Cash, cash equivalents and restricted cash at end of year	141,203	125,574	98,714
Noncash investing and financing activities
Purchases of equipment included in accounts payable and accrued liabilities	$ 682	4,679	773
Noncash additions to property through lease financing arrangements			36,607
Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases		$ 36,607
Conversion of convertible preferred stock to common stock upon closing of initial public offering			561,931
Conversion of convertible preferred stock warrant to common stock warrant upon closing of initial public offering			$ 2,602